Table 5.
Polyunsaturated fatty acids (PUFA) content in the TAG fraction (nmol/g of wet tissue) in white gastrocnemius muscle in the control (standard diet) and high-fat diet (HFD) groups after two-week cannabidiol (CBD) treatment.
| Fatty Acid | Control | CBD | HFD | HFD + CBD |
|---|---|---|---|---|
| (18:2n6c) | 306.57 ± 97.30 | 295.80 ± 47.57 | 1340.05 ± 383.66 a | 879.74 ± 181.45 a,b |
| (20:4n6) | 17.51 ± 3.63 | 16.74 ± 2.51 | 28.85 ± 6.46 a | 30.21 ± 5.40 a |
| (18:3n3) | 31.39 ± 8.98 | 30.24 ± 5.17 | 74.72 ± 21.80 a | 61.33 ± 10.99 a |
| (20:5n3) | 4.63 ± 1.58 | 3.73 ± 1.12 | 3.95 ± 1.20 | 2.89 ± 1.48 a |
| (22:6n3) | 6.12 ± 2.12 | 9.18 ± 3.66 a | 11.56 ± 3.72 a | 16.64 ± 3.28 a,b |
| n-6 PUFAs | 324.08 ± 99.30 | 313.26 ± 49.97 | 1290.09 ± 434.82 a | 909.95 ± 183.75 a,b |
| n-3 PUFAs | 42.86 ± 11.48 | 42.64 ± 8.12 | 90.98 ± 28.53 a | 80.19 ± 11.43 a |
The data are expressed as mean values ± SD, n = 10 in each group. a p < 0.05 indicates a significant difference: the control group vs. the examined group in the white gastrocnemius muscle; b p < 0.05 indicates a significant difference: HFD vs. HFD + CBD in the white gastrocnemius muscle; 18:2n6c (linoleic acid, LA); 20:4n6 (arachidonic acid, AA); 18:3n3 (α-linolenic acid, ALA); 20:5n3 (eicosapentaenoic acid, EPA); 22:6n3 (docosahexaenoic acid, DHA).